JP2013531013A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531013A5
JP2013531013A5 JP2013518686A JP2013518686A JP2013531013A5 JP 2013531013 A5 JP2013531013 A5 JP 2013531013A5 JP 2013518686 A JP2013518686 A JP 2013518686A JP 2013518686 A JP2013518686 A JP 2013518686A JP 2013531013 A5 JP2013531013 A5 JP 2013531013A5
Authority
JP
Japan
Prior art keywords
salt
compound according
disease
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531013A (ja
JP5739527B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042508 external-priority patent/WO2012006203A1/en
Publication of JP2013531013A publication Critical patent/JP2013531013A/ja
Publication of JP2013531013A5 publication Critical patent/JP2013531013A5/ja
Application granted granted Critical
Publication of JP5739527B2 publication Critical patent/JP5739527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518686A 2010-07-07 2011-06-30 RhoキナーゼインヒビターとしてのN−環式−3−(環状カルボニルアミノメチル)ベンズアミド誘導体 Active JP5739527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36203210P 2010-07-07 2010-07-07
US61/362,032 2010-07-07
PCT/US2011/042508 WO2012006203A1 (en) 2010-07-07 2011-06-30 N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013531013A JP2013531013A (ja) 2013-08-01
JP2013531013A5 true JP2013531013A5 (enExample) 2014-08-14
JP5739527B2 JP5739527B2 (ja) 2015-06-24

Family

ID=44533080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518686A Active JP5739527B2 (ja) 2010-07-07 2011-06-30 RhoキナーゼインヒビターとしてのN−環式−3−(環状カルボニルアミノメチル)ベンズアミド誘導体

Country Status (4)

Country Link
US (1) US8697911B2 (enExample)
EP (1) EP2590950B1 (enExample)
JP (1) JP5739527B2 (enExample)
WO (1) WO2012006203A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2630144B1 (en) 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors
CN103420917B (zh) * 2012-05-18 2015-08-19 国药一心制药有限公司 含稠环结构的苯甲酰胺类化合物及其作为抗肿瘤药物应用
WO2014103801A1 (ja) * 2012-12-28 2014-07-03 株式会社新日本科学 イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2015017335A1 (en) * 2013-07-30 2015-02-05 Boehringer Ingelheim International Gmbh Azaindole compounds as modulators of rorc
EP3294871A1 (en) 2015-05-12 2018-03-21 Platod Combination of pharmacological and microfluidic features for improved platelets production
EP3297437A4 (en) * 2015-05-18 2019-02-27 Translational Drug Development Llc HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KINASES
JP6948398B2 (ja) * 2016-10-24 2021-10-13 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物
US10738007B2 (en) 2016-10-24 2020-08-11 Translation Drug Development, LLC Amide compounds as kinase inhibitors, compositions and methods of treatment
WO2018094362A1 (en) 2016-11-21 2018-05-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors
WO2018108156A1 (zh) * 2016-12-16 2018-06-21 成都先导药物开发有限公司 Rock抑制剂及其应用
WO2019058393A1 (en) 2017-09-22 2019-03-28 Jubilant Biosys Limited HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD
US11261184B2 (en) 2017-10-02 2022-03-01 Boehringer Ingelheim International Gmbh [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors
FI3697785T3 (fi) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidatsopyridiiniyhdisteitä pad:n estäjinä
JP7279057B6 (ja) 2017-11-06 2024-02-15 ジュビラント プローデル エルエルシー Pd1/pd-l1活性化の阻害剤としてのピリミジン誘導体
WO2019102494A1 (en) 2017-11-24 2019-05-31 Jubilant Biosys Limited Heterocyclic compounds as prmt5 inhibitors
AU2019234185B2 (en) 2018-03-13 2024-08-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
EP3784226B1 (en) * 2018-04-24 2024-08-14 Translational Drug Development Llc Pyrazole-phenylamide derivatives as inhibitors of the rho-associated protein kinase rock1 and rock2 for the treatment of cancer
CN109678815B (zh) * 2019-01-09 2022-11-29 中国药科大学 N-苄基苯甲酰胺类衍生物及其制备方法与制药用途
WO2023091565A1 (en) * 2021-11-17 2023-05-25 The University Of North Carolina At Chapel Hill Nsd2-targeted chemical degraders and compositions and methods of use thereof
CN116284045A (zh) * 2023-05-18 2023-06-23 西南交通大学 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法
WO2025242921A1 (en) * 2024-05-23 2025-11-27 Storm Therapeutics Limited Processes for the preparation of inhibitory compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20020127605A1 (en) 2000-11-28 2002-09-12 Hamilton Gregory S. Bisubstituted carbocyclic cyclophilin binding compounds and their use
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
US20050209284A1 (en) 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AU2005305140A1 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as CB1 antagonists
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
WO2008079277A1 (en) * 2006-12-22 2008-07-03 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
US8012955B2 (en) 2006-12-28 2011-09-06 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CN103896831A (zh) 2007-08-27 2014-07-02 Abbvie德国有限责任两合公司 4-(4-吡啶基)-苯甲酰胺及其作为rock活性调节剂的应用
PE20090610A1 (es) 2007-08-30 2009-06-11 Takeda Pharmaceutical Derivados de pirazol sustituidos
US8119809B2 (en) 2007-11-16 2012-02-21 Rigel Pharmaceuticals, Inc. AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same
AR071069A1 (es) 2008-03-26 2010-05-26 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2630144B1 (en) 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2013531013A5 (enExample)
JP2013530237A5 (enExample)
JP2013544797A5 (enExample)
JP2012506368A5 (enExample)
JP2018534326A (ja) Ror−ガンマのモジュレーター
HK1211289A1 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2010536761A5 (enExample)
EP3259253A1 (en) Sulfonylureas and related compounds and use of same
EA200801906A1 (ru) ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИМУННОГО ОТВЕТА
JP2013529647A5 (enExample)
WO2009062402A1 (en) Quinazolinone derivatives, the preparation methods and uses thereof
HRP20211002T1 (hr) 1,3-tiazol-2-il supstituirani benzamidi
TN2014000033A1 (fr) Indazoles
CA2540163A1 (en) Thrombin receptor antagonists
AU2015402778B2 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
CN108864057A (zh) 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
JP2014510133A (ja) 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法
EA200800975A1 (ru) ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ
BR112014008412A2 (pt) derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral
DK2804863T3 (en) NEW FORMS AND SALTS OF A dihydropyrrolo- [1,2-C] IMIDAZOLYLALDOSTERONSYNTASE OR aromatase
JP2016529306A5 (enExample)
JP2017522348A5 (enExample)
JP2017522350A5 (enExample)
WO2014028805A1 (en) Pyrrolopyrazoles as n-type calcium channel blockers
JP2013507377A5 (enExample)